Venkatakrishnan J
Indian J Ophthalmol. 2024; 72(8):1216-1218.
PMID: 39078969
PMC: 11451797.
DOI: 10.4103/IJO.IJO_3309_23.
Spit K, Azahaf S, de Blok C, Nanayakkara P
Plast Reconstr Surg Glob Open. 2022; 10(6):e4373.
PMID: 35702355
PMC: 9187172.
DOI: 10.1097/GOX.0000000000004373.
Alvarez-Cuesta E, Madrigal-Burgaleta R, Broyles A, Cuesta-Herranz J, Guzman-Melendez M, Maciag M
World Allergy Organ J. 2022; 15(6):100640.
PMID: 35694005
PMC: 9163606.
DOI: 10.1016/j.waojou.2022.100640.
Yamamoto A, Kamoi S, Matsuda S, Kawase R, Nakanishi K, Suzuki S
Medicines (Basel). 2022; 9(4).
PMID: 35447874
PMC: 9032487.
DOI: 10.3390/medicines9040026.
Tate S, Nishikimi K, Matsuoka A, Otsuka S, Shozu M
Cancers (Basel). 2021; 13(4).
PMID: 33562736
PMC: 7915680.
DOI: 10.3390/cancers13040640.
Rapid Desensitization for Hypersensitivity Reactions to Chemotherapeutic Drugs; A Case Series.
Babaie D, Shamsian B, Momtazmanesh N, Godarzipour H, Amirmoini M, Bashardoust B
Iran J Pharm Res. 2019; 18(2):1047-1051.
PMID: 31531085
PMC: 6706720.
DOI: 10.22037/ijpr.1999.1100664.
Successful resuscitation after cardiac arrest secondary to carboplatin infusion: A case report.
De Zoysa M, Nakamaru N, Kaiser S, Ciccone M, Muderspach L, Matsuo K
Gynecol Oncol Rep. 2018; 23:7-9.
PMID: 29892682
PMC: 5993523.
DOI: 10.1016/j.gore.2017.12.002.
Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies.
Tai Y, Tai Y, Hsu H, Lee S, Chen Y, Chiang Y
Front Pharmacol. 2017; 8:800.
PMID: 29163180
PMC: 5681487.
DOI: 10.3389/fphar.2017.00800.
Introduction to managing patients with recurrent ovarian cancer.
Gabra H
EJC Suppl. 2016; 12(2):2-6.
PMID: 26759525
PMC: 4683381.
DOI: 10.1016/S1359-6349(15)70003-0.
Presentation and Diagnosis of Hypersensitivity to Platinum Drugs.
Caiado J, Castells M
Curr Allergy Asthma Rep. 2015; 15(4):15.
PMID: 26130472
DOI: 10.1007/s11882-015-0515-3.
4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study.
Takase N, Matsumoto K, Onoe T, Kitao A, Tanioka M, Kikukawa Y
Int J Clin Oncol. 2014; 20(3):566-73.
PMID: 25030546
DOI: 10.1007/s10147-014-0731-1.
Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators.
Caiado J, Picard M
Curr Allergy Asthma Rep. 2014; 14(8):451.
PMID: 24951237
DOI: 10.1007/s11882-014-0451-7.
Nanocarriers for delivery of platinum anticancer drugs.
Oberoi H, Nukolova N, Kabanov A, Bronich T
Adv Drug Deliv Rev. 2013; 65(13-14):1667-85.
PMID: 24113520
PMC: 4197009.
DOI: 10.1016/j.addr.2013.09.014.
Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.
Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif M
Met Based Drugs. 2010; 2010.
PMID: 20886011
PMC: 2945654.
DOI: 10.1155/2010/207084.
Pharmaceutical management of ovarian cancer : current status.
Markman M
Drugs. 2008; 68(6):771-89.
PMID: 18416585
DOI: 10.2165/00003495-200868060-00004.
Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions.
Markman M, Hsieh F, Zanotti K, Webster K, Peterson G, Kulp B
J Cancer Res Clin Oncol. 2003; 130(1):25-8.
PMID: 14564516
DOI: 10.1007/s00432-003-0501-3.
Prevention and management of antineoplastic-induced hypersensitivity reactions.
Zanotti K, Markman M
Drug Saf. 2001; 24(10):767-79.
PMID: 11676304
DOI: 10.2165/00002018-200124100-00005.